InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.40
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.79
(
0.00%
)
Bitcoin
65,157.59
(
0.03%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: pcrutch post# 129497

Wednesday, 01/18/2012 10:06:04 AM

Wednesday, January 18, 2012 10:06:04 AM

Post# of 252254
Bayer/ONYX regorafenib in mCRC

Curious what the actual results are

Data are out:

http://www.prnewswire.com/news-releases/phase-iii-data-show-bayers-investigational-compound-regorafenib-bay-73-4506-met-primary-endpoint-showing-statistically-significant-improvement-in-overall-survival-in-patients-with-metastatic-colorectal-cancer-refractory-to-sta-137524158.html

Stat-sig of course on both OS and PFS (expected as the trial was stopped for efficacy) but differences are quite small (which is also something to expect in this setting) - 1.6 and 0.2 months respectively and the price to pay - a big increase in AE.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up